Rebecca Chambers, who serves as the Chief Financial Officer for VERACYTE, INC. (NASDAQ: VCYT), executed a sale of the company's common stock on June 4, 2026. The transaction involved approximately $177,082 worth of shares. According to the filing, these sales were carried out pursuant to a Rule 10b5-1 trading plan. The shares were divested at prices ranging from $48.80 to $50.40 per share. This timing coincides with the stock trading near its 52-week high of $50.71. The stock has delivered an impressive 85% return over the past year. According to InvestingPro analysis, VCYT currently appears overvalued relative to its Fair Value. However, 6 analysts have recently revised earnings upwards. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for VCYT and 1,400+ other US equities.
Separately, on June 2, 2026, Ms. Chambers also disposed of 3,693 shares of common stock at a price of $47.80 per share. This transaction was valued at approximately $176,525. This transaction was related to the withholding of shares to satisfy tax obligations in connection with the vesting of restricted stock units and does not represent a market sale. Following these transactions, Ms. Chambers directly owns 173,280 shares of VERACYTE common stock.
In other recent news, Veracyte Inc. reported significant developments that have caught the attention of investors. The company presented clinical study results at the American Society of Clinical Oncology 2026 Annual Meeting. The presentations focused on their ENZAMET and OPTIMA studies, which evaluated the effectiveness of their tests in predicting chemotherapy benefits for cancer patients. Following these presentations, Canaccord maintained a Hold rating on Veracyte, keeping the price target at $42. Wolfe Research initiated coverage with an Outperform rating and set a price target of $55, reflecting expectations based on future revenue projections. Additionally, Needham raised its price target for Veracyte to $57, maintaining a Buy rating after positive results from the OPTIMA trial, which highlighted Prosigna's Level 1A evidence for chemotherapy benefit prediction.
Veracyte Inc. Follow Analyze VCYT Included in our AI-picked strategies. Review strategies 49.94 ▲+1.25(+2.57%) Closed 49.82 ▼-0.12(-0.24%) After Hours. 1D 1W 1M 6M 1Y 5Y Max Analyze VCYT. Veracyte also announced the commercial launch of the Prosigna Breast Risk of Recurrence test in the U.S. The test is aimed at early-stage hormone-receptor positive breast cancer patients. This test is designed to assess a patient's risk of recurrence and predict the likelihood of benefiting from chemotherapy versus endocrine therapy alone. Furthermore, Veracyte's TrueMRD Monitoring Test for muscle-invasive bladder cancer received Medicare coverage, marking its commercial launch. This coverage is specifically for recurrence monitoring after definitive treatment with curative intent. These recent developments underscore Veracyte's ongoing efforts to enhance cancer diagnostic tools and expand their market presence.